Hba1c Analyzer Market Growth by Regional Segments 2023 ... - Digital Journal
| 086060 Stock | KRW 3,415 65.00 1.94% |
About 55% of GeneBioTech's investors are presently thinking to get in. The analysis of current outlook of investing in GeneBioTech Co suggests that some traders are interested regarding GeneBioTech's prospects. The current market sentiment, together with GeneBioTech's historical and current headlines, can help investors time the market. In addition, many technical investors use GeneBioTech stock news signals to limit their universe of possible portfolio assets.
GeneBioTech |
Hba1c Analyzer Market Growth by Regional Segments 2023 ... Digital Journal
Read at news.google.com
 |
GeneBioTech Fundamental Analysis
We analyze GeneBioTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneBioTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneBioTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
GeneBioTech is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
GeneBioTech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GeneBioTech stock to make a market-neutral strategy. Peer analysis of GeneBioTech could also be used in its relative valuation, which is a method of valuing GeneBioTech by comparing valuation metrics with similar companies.
Peers
GeneBioTech Related Equities
| 058470 | LEENO Industrial | 6.85 | ||||
| 007530 | Youngsin Metal | 3.89 | ||||
| 025750 | Hansol Homedeco | 0.16 | ||||
| 034810 | Haesung Industrial | 0.17 | ||||
| 115480 | CU Medical | 0.58 | ||||
| 013580 | Kyeryong Construction | 2.02 | ||||
| 009900 | Myoung Shin | 2.03 |
Complementary Tools for GeneBioTech Stock analysis
When running GeneBioTech's price analysis, check to measure GeneBioTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneBioTech is operating at the current time. Most of GeneBioTech's value examination focuses on studying past and present price action to predict the probability of GeneBioTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneBioTech's price. Additionally, you may evaluate how the addition of GeneBioTech to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |